Abstract
Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Current Pharmaceutical Design
Title:Current Rapid-Onset Antidepressants and Related Animal Models
Volume: 24 Issue: 22
Author(s): Kuo Yan, Yi-Bing Chen, Jia-Rong Wu, Kuang-Dai Li and Yuan-Lu Cui*
Affiliation:
- Research Center of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No. 88 YuQuan Road, Nankai District, Tianjin, 300193,China
Keywords: Rapid onset, antidepressants, animal models, depression, chronic unpredictable mild stress (CUMS), suspension test.
Abstract: Depression is a common mental disease, and it is one of the most crippling diseases in the world. Although current pharmacotherapies contribute to the treatment of depression, the high incidence of a partial responses or no responses, and delayed onset of the antidepressants, make many patients to experience unsatisfactory results from treatment. In view of the high suicide rate during the period of drug onset, it is critical to find antidepressant drugs with rapid onset for the treatment of depression. This paper mainly reviews some drugs that have rapid antidepressant effect and their mechanisms, including monoaminergic receptor drugs, glutamate receptor drugs, mammalian target of rapamycin (mTOR) signaling agonist, gamma-aminobutyric acid energy (GABAergic) agonist and drug combinations. In addition, we introduce several rodent models currently used to assess antidepressant onset in this review: chronic unpredictable mild stress (CUMS), forced swimming test (FST) and tail suspension test (TST), olfactory bulbectomy (OBX) and other models, which provide a methodological approach for assessing the rapid onset of antidepressant drugs.
Export Options
About this article
Cite this article as:
Yan Kuo, Chen Yi-Bing , Wu Jia-Rong, Li Kuang-Dai and Cui Yuan-Lu *, Current Rapid-Onset Antidepressants and Related Animal Models, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180727115222
DOI https://dx.doi.org/10.2174/1381612824666180727115222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Central Nervous System-Related
Current Bioactive Compounds Chaperone-like Activity of alpha-Crystallin and Other Small Heat Shock Proteins
Current Protein & Peptide Science In Vitro Effects of Nickel on Healthy Non-Allergic Peripheral Blood Mononuclear Cells. The Role of Red Grape Polyphenols
Endocrine, Metabolic & Immune Disorders - Drug Targets Emotion and Destination Memory in Alzheimer’s Disease
Current Alzheimer Research Is Combined Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade Associated with Increased Risk of Cardiovascular Death in Hemodialysis Patients?
Current Hypertension Reviews Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Rutin as a Natural Therapy for Alzheimer's Disease: Insights into its Mechanisms of Action
Current Medicinal Chemistry Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research Analytical Methodologies for Chloramphenicol Residues Determination in Food Matrixes: A Brief Review
Current Pharmaceutical Analysis Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Application of the In Combo Screening Approach For the Discovery of Non-Alkaloid Acetylcholinesterase Inhibitors from Cichorium intybus
Current Drug Discovery Technologies Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide
Central Nervous System Agents in Medicinal Chemistry Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse
Current Alzheimer Research